Myriad Genetics Inc  (MYGN) Trade Now »     Rate MYGN  -  Discuss MYGN  -  Add to Watch List        

Obama-Care Focused on Preventive Medicine

In addition to bullish outlooks for generic drugs and Health IT , President-Elect Obama's healthcare plan plans to focus on public health initiatives and mandated coverage of preventive services such as cancer screenings. The accompanying table presents statistics and the top five rated companies in the ETFI Preventive Medicine Index, including vaccine makers such as Emergent BioSolutions (EBS), diabetes care companies such as Novo Nordisk (NVO), diagnostic companies such as Sequenom (SQNM) and Myriad Geneti

Myriad Genetics, Inc., a biotechnology company, engages in the development and marketing of therapeutic and molecular diagnostic products. The company offers molecular diagnostic products comprising BRACAnalysis for assessing a woman’s risk for breast and ovarian cancer; COLARIS for determining a person’s risk of developing colorectal cancer or uterine cancer; COLARIS AP for assessing a person’s risk of developing colon cancer; MELARIS for determining a person’s risk of developing melanoma; and THERAGUIDE 5-FU for assessing a patient’s risk of developing 5-FU toxicity. It markets these pro

Low interest rates and high liquidity with economic fears of weakness could yield a coming rotation into biotechnology. 

MYGN hit $28 in March, 2006 and formed a large base until November, where it broke to upside and ran up to ~32 on December 11th.  Since then it has been consolidating.  The $30.50-$32.00 level has been accepted by the market and it closes the week high in its range despite a difficult Friday environment for stocks due to payrolls report that is effectively meaningless for biotechnology.